Design Therapeutics, Inc. (DSGN) News
Follow Design Therapeutics, Inc. (DSGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
DSGN says DT-216 delivered biomarker and clinical gains in Friedreich ataxia
DSGN’s DT-216 showed strong proof of concept in Friedreich ataxia, with significant biomarker and functional improvements. The company expects a 12-week efficacy readout in Q1 2027 and says its DM1 program is advancing w
REGULATION | Sep 09, 2026, 07:53 PM UTC
L
Design Therapeutics to participate in 2026 Cantor Fitzgerald healthcare conference chat
Design Therapeutics said management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
Design Therapeutics to participate in 2026 Cantor Fitzgerald conference
Design Therapeutics says it will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
DSGN - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - Click For Rel
DSGN - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 12:01 PM UTC
L
DSGN Design Therapeutics RESULTS: Q2, Q2 operating expenses $22.177M, Q2 Net Income $-20.165M vs. EST $-21.3M, Q2 Operating Income $-22.177M
DSGN Design Therapeutics RESULTS: Q2, Q2 operating expenses $22.177M, Q2 Net Income $-20.165M vs. EST $-21.3M, Q2 Operating Income $-22.177M, Q2 basic EPS $-0.32
EARNINGS | Aug 03, 2026, 12:00 PM UTC
L
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy
Design Therapeutics, Inc. (Nasdaq: DSGN ), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-
EQUITY | Jun 30, 2026, 12:06 PM UTC